Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.38 |
| ▸ | BRS3 | P32247 | 2/20 | 0.37 |
| ▸ | PPM1D | O15297 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9630138 | 0.81 | TLR4 (0.36) | DAOTBK1 | |
| SCHEMBL9630143 | 0.81 | TLR4 (0.36) | DAOTBK1 | |
| SCHEMBL9260065 | 0.80 | DAO (0.44) | DAOPARP14POLBPDGFRBPDGFRA | |
| SCHEMBL28138572 | 0.79 | DAO (0.48) | DAOTHRATHRBTBK1BRS3 | |
| SCHEMBL6565816 | 0.77 | GLRA3 (0.41) | DAOTHRATHRBTBK1PPM1D | |
| SCHEMBL27975645 | 0.77 | DAO (0.45) | DAOTHRATHRBTBK1BRS3 | |
| SCHEMBL16191333 | 0.73 | ALDH1A1 (0.46) | DAOTBK1 | |
| SCHEMBL18722116 | 0.73 | DAO (0.39) | DAOPARP14PDGFRBPDGFRA | |
| SCHEMBL10583043 | 0.73 | CYP2C9 (0.38) | RAB9ASMN1; SMN2 | |
| SCHEMBL8767102 | 0.72 | SIGMAR1 (0.40) | DAOPARP14PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676263-B1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2021-10-06 | — | — | EP | disclosed |
| US-11053230-B2 | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. | 2021-07-06 | — | — | US | disclosed |
| EP-3676263-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2020-07-08 | — | — | EP | disclosed |
| US-20200181128-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2020-06-11 | — | — | US | disclosed |
| EP-3426638-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019043103-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-03-07 | — | — | WO | disclosed |
| US-20190055213-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-02-21 | — | — | US | disclosed |
| EP-3426638-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2019-01-16 | — | — | EP | disclosed |
| CN-109071457-A | Inhibitors of indoleamine 2, 3-dioxygenase | 荷兰转化研究中心有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017153459-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055213-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH2 | DAO 52/4885PARP14 2926/4885THRA 2658/4885 |
| US-11053230-B2 | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | DAO 218/4885PARP14 2573/4885THRA 3389/4885 |
| US-20200181128-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | DAO 218/4885PARP14 2573/4885THRA 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.